Hollenbach E, Schulz C, Lehnert H
Department of Endocrinology and Metabolism, Magdeburg University Hospital, Germany.
Life Sci. 1998;63(9):737-50. doi: 10.1016/s0024-3205(98)00329-4.
In the present study assays were improved for the determination of free catecholamines and 3-methoxy-4-hydroxyphenethyleneglycol (MHPG), the major metabolite of peripheral and central noradrenaline. The compounds were extracted by a fluid phase extraction: a diphenyl boric acid method for the purification of catecholamines and an ethyl acetate extraction for MHPG were used, respectively. High-performance liquid chromatography with electrochemical detection was employed for quantitative analysis. In previous studies, significant differences between plasma concentrations of these substances in normal volunteers and hospital patients were demonstrated. Therefore, we established valid reference values for a hospital population. Blood and urine samples of 59 patients without disorders and medication affecting catecholamine synthesis and metabolism or the activity of the sympatho-adrenal system were collected and analyzed for free and total (free plus conjugated) MHPG, noradrenaline (NA), adrenaline (A) and dopamine (DA); total MHPG was assayed after enzymatic hydrolysis of conjugates. Our data clearly demonstrate that these methods are sensitive, specific, rapid, and can easily be standardized. The intra- and inter-assay precision were high (CV 2.6-5.3% and 4.3-6.9% for plasma, CV 3.8-4.9% and 5.1-8.2% for urine, respectively). For plasma, the mean concentrations +/- SD were determined to be 20.82+/-4.70 pmol/ml for free MHPG, 68.43+/-16.21 pmol/ml for total MHPG, 2.11+/-0.24 pmol/ml for NA and 0.31+/-0.08 pmol/ml for A. For 24h-urine the mean concentrations +/-SD were determined to be 0.44+/-0.13 mmol/24h for free MHPG, 8.79+/-2.13 mmol/24h for total MHPG, 169.8+/-58.25 nmol/24h for NA, 62.19+/-21.79 nmol/24h for A and 757.2+/-382.6 nmol/24h for DA. In summary, these novel and rapid methods can clearly be employed in a routine clinical setting.
在本研究中,对游离儿茶酚胺和3-甲氧基-4-羟基苯乙二醇(MHPG,外周和中枢去甲肾上腺素的主要代谢产物)的测定方法进行了改进。这些化合物通过液相萃取法提取:分别采用二苯基硼酸法纯化儿茶酚胺,用乙酸乙酯萃取法提取MHPG。采用高效液相色谱-电化学检测法进行定量分析。在先前的研究中,已证明正常志愿者和医院患者血浆中这些物质的浓度存在显著差异。因此,我们为医院人群建立了有效的参考值。收集了59例无影响儿茶酚胺合成与代谢或交感-肾上腺系统活性的疾病及用药情况的患者的血液和尿液样本,分析游离和总(游离加结合型)MHPG、去甲肾上腺素(NA)、肾上腺素(A)和多巴胺(DA);结合物经酶水解后测定总MHPG。我们的数据清楚地表明,这些方法灵敏、特异、快速,且易于标准化。批内和批间精密度均较高(血浆批内CV为2.6 - 5.3%,批间CV为4.3 - 6.9%;尿液批内CV为3.8 - 4.9%,批间CV为5.1 - 8.2%)。血浆中,游离MHPG的平均浓度±标准差为20.82±4.70 pmol/ml,总MHPG为68.43±16.21 pmol/ml,NA为2.11±0.24 pmol/ml,A为0.31±0.08 pmol/ml。24小时尿液中,游离MHPG的平均浓度±标准差为0.44±0.13 mmol/24h,总MHPG为8.79±2.13 mmol/24h,NA为169.8±58.25 nmol/24h,A为62.19±21.79 nmol/24h,DA为757.2±382.6 nmol/24h。总之,这些新颖且快速的方法可明确应用于常规临床环境。